See more : Hersha Hospitality Trust (HT-PD) Income Statement Analysis – Financial Results
Complete financial analysis of Crescita Therapeutics Inc. (CTX.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Crescita Therapeutics Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dunedin Income Growth Investment Trust PLC (DIG.L) Income Statement Analysis – Financial Results
- Terranueva Corporation (TEQ.CN) Income Statement Analysis – Financial Results
- Arvee Laboratories (India) Ltd. (ARVEE.NS) Income Statement Analysis – Financial Results
- Glanbia plc (GLB.L) Income Statement Analysis – Financial Results
- AltEnergy Acquisition Corp. (AEAEW) Income Statement Analysis – Financial Results
Crescita Therapeutics Inc. (CTX.TO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crescitatherapeutics.com
About Crescita Therapeutics Inc.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.52M | 23.53M | 16.77M | 15.64M | 22.34M | 16.63M | 12.01M | 3.50M | 857.00K | 830.00K |
| Cost of Revenue | 7.16M | 10.34M | 6.76M | 4.37M | 5.80M | 5.54M | 4.85M | 2.34M | 501.00K | 279.00K |
| Gross Profit | 10.36M | 13.18M | 10.01M | 11.27M | 16.54M | 11.09M | 7.17M | 1.17M | 356.00K | 551.00K |
| Gross Profit Ratio | 59.15% | 56.03% | 59.72% | 72.08% | 74.03% | 66.69% | 59.66% | 33.36% | 41.54% | 66.39% |
| Research & Development | 699.00K | 609.00K | 634.00K | 1.10M | 1.38M | 1.06M | 1.11M | 2.02M | 9.07M | 7.47M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.12M | 10.57M | 8.72M | 7.13M | 8.46M | 10.06M | 12.25M | 13.72M | 6.65M | 6.56M |
| Other Expenses | 1.51M | 1.47M | 1.38M | 1.49M | 1.73M | 455.00K | 12.25M | 13.72M | 6.65M | 6.56M |
| Operating Expenses | 12.32M | 12.65M | 10.73M | 9.72M | 11.57M | 11.13M | 13.36M | 15.74M | 15.72M | 14.03M |
| Cost & Expenses | 19.48M | 23.00M | 17.49M | 14.09M | 17.37M | 16.67M | 18.20M | 18.07M | 16.22M | 14.31M |
| Interest Income | 507.00K | 260.00K | 182.00K | 291.00K | 276.00K | 110.00K | 64.00K | 124.00K | 0.00 | 0.00 |
| Interest Expense | 85.00K | 158.00K | 236.00K | 252.00K | 679.00K | 603.00K | 446.00K | 123.00K | 40.00K | 52.00K |
| Depreciation & Amortization | 1.51M | 1.47M | 1.38M | 1.49M | 1.73M | 1.15M | 1.16M | 382.00K | 37.00K | 300.00K |
| EBITDA | 45.00K | 2.09M | 598.00K | 2.26M | 5.59M | 2.40M | -9.65M | -14.43M | -7.39M | -14.25M |
| EBITDA Ratio | 0.26% | 9.36% | 5.07% | 25.61% | 25.51% | 10.07% | -41.32% | -400.34% | -1,788.21% | -1,587.71% |
| Operating Income | -1.96M | 732.00K | -529.00K | 2.51M | 3.97M | -37.00K | -6.57M | -14.57M | -15.36M | -13.48M |
| Operating Income Ratio | -11.16% | 3.11% | -3.15% | 16.07% | 17.77% | -0.22% | -54.69% | -415.78% | -1,792.53% | -1,623.86% |
| Total Other Income/Expenses | 426.00K | -125.00K | -480.00K | -1.04M | -1.79M | 686.00K | -5.04M | -230.00K | -69.00K | -1.12M |
| Income Before Tax | -1.53M | 404.00K | -1.01M | 520.00K | 3.18M | 649.00K | -11.26M | -14.80M | -15.45M | -14.60M |
| Income Before Tax Ratio | -8.73% | 1.72% | -6.02% | 3.32% | 14.24% | 3.90% | -93.71% | -422.35% | -1,802.57% | -1,759.16% |
| Income Tax Expense | 456.00K | -458.00K | 96.00K | 483.00K | 1.33M | -1.77M | 651.00K | -2.10M | 40.00K | 52.00K |
| Net Income | -1.99M | 862.00K | -1.11M | 37.00K | 1.86M | 2.40M | -11.46M | -14.95M | -15.45M | -14.60M |
| Net Income Ratio | -11.33% | 3.66% | -6.59% | 0.24% | 8.30% | 14.41% | -95.41% | -426.60% | -1,802.57% | -1,759.16% |
| EPS | -0.10 | 0.04 | -0.05 | 0.00 | 0.09 | 0.12 | -0.82 | -1.22 | -1.41 | -1.46 |
| EPS Diluted | -0.10 | 0.04 | -0.05 | 0.00 | 0.08 | 0.12 | -0.82 | -1.17 | -1.35 | -1.39 |
| Weighted Avg Shares Out | 20.26M | 20.69M | 20.76M | 20.66M | 20.94M | 19.71M | 13.96M | 12.25M | 10.93M | 10.03M |
| Weighted Avg Shares Out (Dil) | 20.26M | 21.00M | 20.76M | 20.97M | 22.50M | 19.71M | 13.96M | 12.81M | 11.43M | 10.49M |
Source: https://incomestatements.info
Category: Stock Reports